Effects of pubertal cannabinoid administration on attentional set-shifting and dopaminergic hyper-responsivity in a developmental disruption model of schizophrenia

International Journal of Neuropsychopharmacology

Volumn 18, Issue 2, 2015, Pages 1-10

  Gomes, Felipe V ^a   Guimaraes, Francisco S ^a   Grace, Anthony A ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Adolescence; Cannabinoid; Dopamine; MAM treatment; Schizophrenia

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; AMPHETAMINE; CANNABINOID; METHYLAZOXYMETHANOL; BENZOXAZINE DERIVATIVE; CENTRAL STIMULANT AGENT; METHYLAZOXYMETHANOL ACETATE; MORPHOLINE DERIVATIVE; NAPHTHALENE DERIVATIVE;

ADOLESCENT; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENTION; CONTROLLED STUDY; DISEASE MODEL; DOPAMINERGIC ACTIVITY; DOPAMINERGIC NERVE CELL; FEMALE; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; PUBERTY; RAT; RISK FACTOR; SCHIZOPHRENIA; TASK PERFORMANCE; VENTRAL TEGMENTUM; ANALOGS AND DERIVATIVES; ANIMAL; DRUG EFFECTS; EXECUTIVE FUNCTION; GROWTH, DEVELOPMENT AND AGING; MOTOR ACTIVITY; NEUROPSYCHOLOGICAL TEST; PATHOPHYSIOLOGY; PHYSIOLOGY; PREGNANCY; PRENATAL EXPOSURE; PSYCHOLOGY; SPRAGUE DAWLEY RAT;

AMPHETAMINE; ANIMALS; ATTENTION; BENZOXAZINES; CANNABINOIDS; CENTRAL NERVOUS SYSTEM STIMULANTS; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; EXECUTIVE FUNCTION; FEMALE; MALE; METHYLAZOXYMETHANOL ACETATE; MORPHOLINES; MOTOR ACTIVITY; NAPHTHALENES; NEUROPSYCHOLOGICAL TESTS; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RATS, SPRAGUE-DAWLEY; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; VENTRAL TEGMENTAL AREA;

EID: 84931263669     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1093/ijnp/pyu018     Document Type: Article

References (77)

1. Abdullaev Y, Posner MI, Nunnally R, Dishion TJ (2010) Functional MRI evidence for inefficient attentional control in adolescent chronic cannabis abuse. Behav Brain Res 215:45-57.
2. Abi-Dargham A (2004) Do we still believe in the dopamine hypothesis? New data bring new evidence. Int J Neuropsychopharmacol 7(Suppl 1):S1-5.
3. Agid O, Kapur S, Arenovich T, Zipursky RB (2003) Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry, 60:1228-1235.
4. Arseneault L, Cannon M, Fisher HL, Polanczyk G, Moffitt TE, Caspi A (2011) Childhood trauma and children's emerging psychotic symptoms: A genetically sensitive longitudinal cohort study. Am J Psychiatry 168:65-72.
5. Arseneault L, Cannon M, Witton J, Murray RM (2004) Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry 184:110-117.
6. Belujon P, Patton MH, Grace AA (2013) Disruption of prefrontal cortical-hippocampal balance in a developmental model of schizophrenia: reversal by sulpiride. Int J Neuropsychopharmacol 16:507-512.
7. Birrell JM, Brown VJ (2000) Medial frontal cortex mediates perceptual attentional set shifting in the rat. J Neurosci 20: 4320-4324.
8. Casadio P, Fernandes C, Murray RM, Di Forti M (2011) Cannabis use in young people: the risk for schizophrenia. Neurosci Biobehav Rev 35:1779-1787.
9. Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H, Taylor A, Arseneault L, Williams B, Braithwaite A, Poulton R, Craig IW (2005) Moderation of the effect of adolescentonset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry 57:1117-1127.
10. Cass DK, Flores-Barrera E, Thomases DR, Vital WF, Caballero A, Tseng KY (2014) CB1 cannabinoid receptor stimulation during adolescence impairs the maturation of GABA function in the adult rat prefrontal cortex. Mol Psychiatry 19:536-543.
11. Ceci C, Mela V, Macri S, Marco EM, Viveros MP, Laviola G (2014) Prenatal corticosterone and adolescent URB597 administration modulate emotionality and CB1 receptor expression in mice. Psychopharmacology (Berl) 231:2131-2144.
12. Cifelli P, Grace AA (2012) Pilocarpine-induced temporal lobe epilepsy in the rat is associated with increased dopamine neuron activity. Int J Neuropsychopharmacol 15:957-964.
13. Cleveland HH, Wiebe RP (2008) Understanding the association between adolescent marijuana use and later serious drug use: gateway effect or developmental trajectory? Dev Psychopathol 20:615-632.
14. Dean B, Bradbury R, Copolov DL (2003) Cannabis-sensitive dopaminergic markers in postmortem central nervous system: changes in schizophrenia. Biol Psychiatry 53:585-592.
15. Degenhardt L, Hall W (2006) Is cannabis use a contributory cause of psychosis? Can J Psychiatry 51:556-565.
16. Dekker N, Linszen DH, De Haan L (2009) Reasons for cannabis use and effects of cannabis use as reported by patients with psychotic disorders. Psychopathology 42:350-360.
17. Dias R, Robbins TW, Roberts AC (1997) Dissociable forms of inhibitory control within prefrontal cortex with an analog of the Wisconsin Card Sort Test: restriction to novel situations and independence from "on-line" processing. J Neurosci 17:9285-9297.
18. Du Y, Grace AA (2013) Peripubertal Diazepam Administration Prevents the Emergence of Dopamine System Hyperresponsivity in the MAM Developmental Disruption Model of Schizophrenia. Neuropsychopharmacology 38:1881-1888.
19. Featherstone RE, Rizos Z, Nobrega JN, Kapur S, Fletcher PJ (2007) Gestational methylazoxymethanol acetate treatment impairs select cognitive functions: parallels to schizophrenia. Neuropsychopharmacology 32:483-492.
20. Fergusson DM, Poulton R, Smith PF, Boden JM (2006) Cannabis and psychosis. BMJ 332:172-175.
21. Fernandez-Ruiz J, Hernandez M, Ramos JA (2010) Cannabinoiddopamine interaction in the pathophysiology and treatment of CNS disorders. CNS Neurosci Ther 16:e72-91.
22. Flagstad P, Mork A, Glenthoj BY, van Beek J, Michael-Titus AT, Didriksen M (2004) Disruption of neurogenesis on gestational day 17 in the rat causes behavioral changes relevant to positive and negative schizophrenia symptoms and alters amphetamine-induced dopamine release in nucleus accumbens. Neuropsychopharmacology 29:2052-2064.
23. French ED (1997) delta9-Tetrahydrocannabinol excites rat VTA dopamine neurons through activation of cannabinoid CB1 but not opioid receptors. Neurosci Lett 226:159-162.
24. Fried PA, James DS, Watkinson B (2001) Growth and pubertal milestones during adolescence in offspring prenatally exposed to cigarettes and marihuana. Neurotoxicol Teratol 23:431-436.
25. Gardner EL (2005) Endocannabinoid signaling system and brain reward: emphasis on dopamine. Pharmacol Biochem Behav 81:263-284.
26. Gastambide F, Cotel MC, Gilmour G, O'Neill MJ, Robbins TW, Tricklebank MD (2012) Selective remediation of reversal learning deficits in the neurodevelopmental MAM model of schizophrenia by a novel mGlu5 positive allosteric modulator. Neuropsychopharmacology 37:1057-1066.
27. Gill KM, Grace AA (2014) Corresponding decrease in neuronal markers signals progressive parvalbumin neuron loss in MAM schizophrenia model. Int J Neuropsychopharmacol 17:1609-1619.
28. Gleason KA, Birnbaum SG, Shukla A, Ghose S (2012) Susceptibility of the adolescent brain to cannabinoids: long-term hippocampal effects and relevance to schizophrenia. Transl Psychiatry 2:e199.
29. Goto Y, Grace AA (2006) Alterations in medial prefrontal cortical activity and plasticity in rats with disruption of cortical development. Biol Psychiatry 60:1259-1267.
30. Grace AA, Bunney BS (1983) Intracellular and extracellular electrophysiology of nigral dopaminergic neurons-1. Identification and characterization. Neuroscience 10:301-315.
31. Gregg L, Barrowclough C, Haddock G (2007) Reasons for increased substance use in psychosis. Clin Psychol Rev 27: 494-510.
32. Harrison PJ, Weinberger DR (2005) Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 10:40-68.
33. Hashimoto T, Volk DW, Eggan SM, Mirnics K, Pierri JN, Sun Z, Sampson AR, Lewis DA (2003) Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. J Neurosci 23:6315-6326.
34. Kelley AE, Schochet T, Landry CF (2004) Risk taking and novelty seeking in adolescence: introduction to part I. Ann NY Acad Sci 1021:27-32.
35. Kolliakou A, Joseph C, Ismail K, Atakan Z, Murray RM (2011) Why do patients with psychosis use cannabis and are they ready to change their use? Int J Dev Neurosci 29:335-346.
36. Kuepper R, van Os J, Lieb R, Wittchen HU, Henquet C (2011) Do cannabis and urbanicity co-participate in causing psychosis? Evidence from a 10-year follow-up cohort study. Psychol Med 41:2121-2129.
37. Leeson VC, Robbins TW, Matheson E, Hutton SB, Ron MA, Barnes TR, Joyce EM (2009) Discrimination learning, reversal, and setshifting in first-episode schizophrenia: stability over six years and specific associations with medication type and disorganization syndrome. Biol Psychiatry 66:586-593.
38. Pen GL, Jay TM, Krebs MO (2011) Effect of antipsychotics on spontaneous hyperactivity and hypersensitivity to MK- 801-induced hyperactivity in rats prenatally exposed to methylazoxymethanol. J Psychopharmacol 25:822-835.
39. Lewis DA, Hashimoto T, Volk DW (2005) Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 6:312-324.
40. Lodge DJ, Behrens MM, Grace AA (2009) A loss of parvalbumincontaining interneurons is associated with diminished oscil latory activity in an animal model of schizophrenia. J Neurosci 29:2344-2354.
41. Lodge DJ, Grace AA (2007) Aberrant hippocampal activity underlies the dopamine dysregulation in an animal model of schizophrenia. J Neurosci 27:11424-11430.
42. Lodge DJ, Grace AA (2009) Gestational methylazoxymethanol acetate administration: a developmental disruption model of schizophrenia. Behav Brain Res 204:306-312.
43. Lodge DJ, Grace AA (2012) Divergent activation of ventromedial and ventrolateral dopamine systems in animal models of amphetamine sensitization and schizophrenia. Int J Neuropsychopharmacol 15:69-76.
44. Malone DT, Taylor DA (2006) The effect of Delta9-tetrahydrocannabinol on sensorimotor gating in socially isolated rats. Behav Brain Res 166:101-109.
45. Marco EM, Granstrem O, Moreno E, Llorente R, Adriani W, Laviola G, Viveros MP (2007) Subchronic nicotine exposure in adolescence induces long-term effects on hippocampal and striatal cannabinoid-CB1 and mu-opioid receptors in rats. Eur J Pharmacol 557:37-43.
46. Martin CA, Kelly TH, Rayens MK, Brogli BR, Brenzel A, Smith WJ, Omar HA (2002) Sensation seeking, puberty, and nicotine, alcohol, and marijuana use in adolescence. J Am Acad Child Adolesc Psychiatry 41:1495-1502.
47. McAlonan K, Brown VJ (2003) Orbital prefrontal cortex mediates reversal learning and not attentional set shifting in the rat. Behav Brain Res 146:97-103.
48. Moore H, Jentsch JD, Ghajarnia M, Geyer MA, Grace AA (2006) A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: implications for the neuropathology of schizophrenia. Biol Psychiatry 60:253-264.
49. O'Shea M, Singh ME, McGregor IS, Mallet PE (2004) Chronic cannabinoid exposure produces lasting memory impairment and increased anxiety in adolescent but not adult rats. J Psychopharmacol 18:502-508.
50. Pen GL, Jay TM, Krebs MO (2011) Effect of antipsychotics on spontaneous hyperactivity and hypersensitivity to MK- 801-induced hyperactivity in rats prenatally exposed to methylazoxymethanol. J Psychopharmacol 25:822-835.
51. Penschuck S, Flagstad P, Didriksen M, Leist M, Michael-Titus AT (2006) Decrease in parvalbumin-expressing neurons in the hippocampus and increased phencyclidine-induced locomotor activity in the rat methylazoxymethanol (MAM) model of schizophrenia. Eur J Neurosci 23:279-284.
52. Quinn HR, Matsumoto I, Callaghan PD, Long LE, Arnold JC, Gunasekaran N, Thompson MR, Dawson B, Mallet PE, Kashem MA, Matsuda-Matsumoto H, Iwazaki T, McGregor IS (2008) Adolescent rats find repeated Delta(9)-THC less aversive than adult rats but display greater residual cognitive deficits and changes in hippocampal protein expression following exposure. Neuropsychopharmacology 33:1113-1126.
53. Rapoport JL, Addington AM, Frangou S, Psych MR (2005) The neurodevelopmental model of schizophrenia: update 2005. Mol Psychiatry 10:434-449.
54. Reynolds GP, Beasley CL, Zhang ZJ (2002) Understanding the neurotransmitter pathology of schizophrenia: selective deficits of subtypes of cortical GABAergic neurons. J Neural Transm 109:881-889.
55. Rubino T, Realini N, Braida D, Alberio T, Capurro V, Vigano D, Guidali C, Sala M, Fasano M, Parolaro D (2009) The depressive phenotype induced in adult female rats by adolescent exposure to THC is associated with cognitive impairment and altered neuroplasticity in the prefrontal cortex. Neurotox Res 15:291-302.
56. Rubino T, Realini N, Braida D, Guidi S, Capurro V, Vigano D, Guidali C, Pinter M, Sala M, Bartesaghi R, Parolaro D (2009) Changes in hippocampal morphology and neuroplasticity induced by adolescent THC treatment are associated with cognitive impairment in adulthood. Hippocampus 19:763-772.
57. Schneider M (2013) Adolescence as a vulnerable period to alter rodent behavior. Cell Tissue Res 354:99-106.
58. Schneider M, Drews E, Koch M (2005) Behavioral effects in adult rats of chronic prepubertal treatment with the cannabinoid receptor agonist WIN 55, 212-2. Behav Pharmacol 16:447-454.
59. Schneider M, Koch M (2002) The cannabinoid agonist WIN 55, 212-2 reduces sensorimotor gating and recognition memory in rats. Behav Pharmacol 13:29-37.
60. Schneider M, Koch M (2003) Chronic pubertal, but not adult chronic cannabinoid treatment impairs sensorimotor gating, recognition memory, and the performance in a progressive ratio task in adult rats. Neuropsychopharmacology 28:1760-1769.
61. Schneider M, Koch M (2005) Deficient social and play behavior in juvenile and adult rats after neonatal cortical lesion: effects of chronic pubertal cannabinoid treatment. Neuropsychopharmacology 30:944-957.
62. Schneider M, Koch M (2007) The effect of chronic peripubertal cannabinoid treatment on deficient object recognition memory in rats after neonatal mPFC lesion. Eur Neuropsychopharmacol 17:180-186.
63. Schneider M, Schomig E, Leweke FM (2008) Acute and chronic cannabinoid treatment differentially affects recognition memory and social behavior in pubertal and adult rats. Addict Biol 13:345-357.
64. Spano MS, Fattore L, Cadeddu F, Fratta W, Fadda P (2013) Chronic cannabinoid exposure reduces phencyclidine-induced schizophrenia- like positive symptoms in adult rats. Psychopharmacoloy (Berl) 225:531-542.
65. Stefanis NC, Delespaul P, Henquet C, Bakoula C, Stefanis CN, Van Os J (2004) Early adolescent cannabis exposure and positive and negative dimensions of psychosis. Addiction 99:1333-1341.
66. Tait DS, Chase EA, Brown VJ (2014) Attentional set-shifting in rodents: a review of behavioural methods and pharmacological results. Curr Pharm Des 20:5046-5059.
67. Talamini LM, Ellenbroek B, Koch T, Korf J (2000) Impaired sensory gating and attention in rats with developmental abnormalities of the mesocortex. Implications for schizophrenia. Ann NY Acad Sci 911:486-494.
68. Tanda G, Pontieri FE, Di Chiara G (1997) Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 276:2048-2050.
69. Ungless MA, Grace AA (2012) Are you or aren't you? Challenges associated with physiologically identifying dopamine neurons. Trends Neurosci 35:422-430.
70. van Laar M, van Dorsselaer S, Monshouwer K, de Graaf R (2007) Does cannabis use predict the first incidence of mood and anxiety disorders in the adult population? Addiction 102:1251-1260.
71. van Os J, Kenis G, Rutten BP (2010) The environment and schizophrenia. Nature 468:203-212.
72. Valenti O, Cifelli P, Gill KM, Grace AA (2011) Antipsychotic drugs rapidly induce dopamine neuron depolarization block in a developmental rat model of schizophrenia. J Neurosci 31:12330-12338.
73. Vigano D, Guidali C, Petrosino S, Realini N, Rubino T, Di Marzo V, Parolaro D (2009) Involvement of the endocannabinoid system in phencyclidine-induced cognitive deficits modelling schizophrenia. Int J Neuropsychopharmacol 12:599-614.
74. Wilson RI, Nicoll RA (2002) Endocannabinoid signaling in the brain. Science 296:678-682.
75. Wu X, French ED (2000) Effects of chronic delta9-tetrahydrocannabinol on rat midbrain dopamine neurons: an electrophysiological assessment. Neuropharmacology 39:391-398.
76. Zamberletti E, Beggiato S, Steardo L, Jr., Prini P, Antonelli T, Ferraro L, Rubino T, Parolaro D (2014) Alterations of prefrontal cortex GABAergic transmission in the complex psychotic-like phenotype induced by adolescent delta-9-tetrahydrocannabinol exposure in rats. Neurobiol Dis 63:35-47.
77. Zimmerman EC, Bellaire M, Ewing SG, Grace AA (2013) Abnormal stress responsivity in a rodent developmental disruption model of schizophrenia. Neuropsychopharmacology 38:2131-2139.